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Two distinct etiologies of head and neck squamous cell carcinoma (HNSCC) have been proposed, DNA damage owing to tobacco
and alcohol exposure and human papillomavirus (HPV) oncogene-mediated transformation. Common genetic alterations in HNSCC
include TP53 mutations, 11q13 amplification (amp) and CDKN2A/p16 mutations or promoter methlyation. However, in HPVþ
HNSCC it is frequent to observe wild-type TP53 and expression of p16. The relationship of this unusual pattern with 11q13 amp has
not been tested. In a retrospective study on 125 HNSCC patients, only 17% (five out of 30) of HPVþ vs 44% (39 out of 89) of HPV
  tumours expressed 11q13 amp (adjusted odds ratio (OR)¼0.2, 95% confidence interval (CI)¼0.1–0.6). A subpopulation of
tumours (n¼69) were classified according to the three molecular markers, TP53, p16 and 11q13 amp. In addition to wild-type TP53,
and p16 expression, HPVþ tumours were more likely not to be amplified at 11q13 (OR¼6.5, 95% CI¼1.8–23.9). As HPVþ
HNSCC lack the genetic alterations which are common in other tumours, we hypothesise that HPV infection may represent an early
event in the HNSCC carcinogenic process, thus suggesting a distinct molecular pathway.
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Although the majority of cases of head and neck squamous cell
carcinoma (HNSCC) are attributed to tobacco and alcohol
consumption (Blot et al, 1988; Merletti et al, 1989; Franceschi
et al, 1990; Franceschi et al, 1999), morphologic signs of human
papillomavirus (HPV) infection and detection of the viral antigens
in oral squamous cell carcinomas were first reported in 1983
(Syrjanen et al, 1983). Increasing evidence from large case–control
studies of HPV prevalence in head and neck tumours suggests that
this virus may be an additional independent risk factor for a subset
(B25%) of HNSCC (Smith et al, 1998; Gillison et al, 2000; Herrero
et al, 2003).
Head and neck squamous cell carcinoma frequently carries
numerous genetic alterations, such as mutations, chromosomal
losses, gains and amplifications (amp) (Gollin, 2001). Common
genetic alterations in HNSCC involve TP53, CDKN2A/p16 and
chromosomal band 11q13. Amplification of 11q13 is among the
most common sites of gene amplification, observed in a number of
cancers (Schraml et al, 1999), and in approximately 45% of HNSCC
(Lese et al, 1995; Schuuring, 1995; Gollin, 2001). A number of
putative oncogenes map to this region; among them, CCND1
(cyclin D1) is thought to play a role in tumorigenesis. Cyclin D1 is
an important cell cycle protein that binds cyclin-dependent kinase
(CDK) 4 or 6 to phosphorylate and inactivate the RB1 protein
thus driving the cell from G1 into S-phase. Therefore, over-
expression of cyclin D1 may lead to deregulate cell cycling from
G1 to S-phase and may result in a selective growth advantage for
the affected cell.
CDKN2A/p16 opposes cyclin D1 function by negatively regulat-
ing RB1 phosphorylartion and a genetic (loss of heterozygosity
(LOH)) or epigenetic (promoter methylation) alteration in this
gene is frequently observed, resulting in a lack of p16 expression
in most HNSCC (Weber et al, 2003). TP53, also is a frequently
mutated tumour-suppressor gene in a number of cancers,
including about 45% of HNSCC (Sidransky, 1995).
In contrast to most HNSCC, HPV-positive tumours are more
likely to have wild-type TP53. Human papillomavirus-infected
cells accomplish G1 to S-phase transition through the targeted
degradation of pRb by the viral E7 oncoprotein and consequently,
CDKN2A/p16 is overexpressed. Correlations between genetic
alterations at TP53, 11q13 and p16 expression with HPV have
not been evaluated. We report a retrospective study examining the
association of HPV with these molecular risk factors (TP53
mutation, p16 protein expression and 11q13 amp) in patients with
first primary head and neck tumours.
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Study population
The study population (N¼185) included patients undergoing
surgical resection of their tumours between September 1992 and
February 1997, following informed consent under a protocol
approved by the University of Pittsburgh Biomedical Institutional
Review Board. Patients with recurrent tumours, second primaries
and metastatic tumours (lymph node and distant) at the time of
enrollment were excluded from this analysis (n¼58). The
remaining subjects (n¼127), with first primary tumours were
enrolled. Human papillomavirus could be tested in only 125 of 127
tumours; therefore, the number of patients included in this
analysis was 125.
Head and neck database
The head and neck database was established by CCRR, JSW
and JLW in June 2004. Information, including demographics,
smoking and alcohol use, family history, tumour site, clinical
characteristics of the initial primary tumour and subsequent
tumours, follow-up data (such as disease outcome and time to
next disease occurrence) through May 2004 were obtained
from the University of Pittsburgh Tumor Registry. Patients’
clinical and demographic information from the Tumor Registry
was re-verified from each patient’s original deidentified and
coded questionnaires, pathology and surgical reports. All data
from the Tumor Registry was combined with the corresponding
patient’s laboratory data (i.e. TP53 mutation, 11q13 amp, p16
expression and HPV status and genotype) to form the head and
neck database. This database contains clinical, treatment and
follow-up information for the first surgical resection at the time of
enrollment and all subsequent resections for all patients enrolled
in the study.
Smoking status was defined as follows: never smoker (never
smoked), current smoker (recorded as an ever smoker who had
not quit at the time of enrollment), former smoker (quit smoking
at least 1 month before enrollment in the study). Alcohol use was
defined as follows: never drinker (never consumed alcohol),
current drinker (had not quit alcohol consumption at the time of
enrollment) and former drinker (quit alcohol consumption before
enrollment). For the duration of alcohol use, each patient was
categorised as never (never consumed alcohol), short-term
(consumed alcohol socially or for less than 10 years), or long-
term (consumed alcohol for 10 years or more, irrespective of
consumption habit) users. Tumour site, histology, stage and grade
were classified according to the American Joint Committee on
Cancer (AJCC) ICD9 codes, ICD-morphology, stage and grade
classification, respectively. Sites of the oral cavity included cheek,
retromolar area, alveolar ridge, oral tongue, palate, floor of mouth
and overlapping lesions of other and unspecified parts of the
mouth. The oropharynx included sites involving the base of
tongue, soft palate, tonsil and overlapping lesions of the oral cavity
and pharynx. Analyses of TP53 mutation status (Law et al, 1995)
and (Gollin et al, unpublished data), p16 immunohistochemistry
(unpublished data) and 11q13 amp (Shuster et al, 2000; Lese et al,
1995) were performed in earlier unpublished studies unless
otherwise noted. Briefly, TP53 mutation status was determined
by automated sequencing of exons 5–8, p16 immunohisto-
chemistry was performed on paraffin sections of formaldehyde-
fixed tissue using a monoclonal antibody to full length human
p16 protein (Vector Labs, Burlingame, CA, USA). Cells were
considered p16-positive if more than 5% of cells in a tumour island
or mucosal surface stained visibly stronger than the negative
control. When more than 5% of the cells were stained weakly, the
result was considered to be weakly positive for p16. Amplification
of 11q13 was assessed using fluorescence in situ hybridisation
(FISH) probes for FGF3/INT2, FGF4/HST1 or CCND1 (Lese et al,
1995; Shuster et al, 2000).
Human papilloma virus testing and genotyping
Extracted DNA was available from 125 tumours. Polymerase chain
reaction (PCR) amplification of a b-globin gene fragment was
performed using the PCO4 and GH20 primers (Saiki et al, 1986) to
confirm that the extracted DNA was amplifiable. All samples were
positive for the b-globin amplicon (n¼125). Human papilloma-
virus status was determined by a nested real-time PCR assay using
consensus HPV primers PGMY09/11/HMB01 (Gravitt et al, 2000)
and GP5þ/6þ primers (de Roda Husman et al, 1995). DNA
amplification was performed using the LightCycler
s FastStart
DNA Master
PLUS SYBR Green I kit on a LightCycler
s 2.0 system
(Roche Diagnostics, Indianapolis, IN, USA). All DNA amplification
reactions were set up according to the manufacturer’s protocol
(using 3mM MgCl2 and 0.3mM each PGMY09/11/HMB01 primers
(for the primary PCR reaction) or 1.0mM each GP5þ/GP6þ
primers (for the nested PCR reaction)) and were performed in a
separate room from that used for the DNA amplification steps.
For all HPV-positive samples from the previously described
PCR protocol, confirmation of the appropriately sized amplicon
was carried out by running an aliquot of each sample on a 10%
PAGEr
s polyacrylamide gel (Cambrex Bio Science, Rockland, ME,
USA), at 250 volts for 55min. The gel was stained with the highly
sensitive GelStar
s nucleic acid stain (Cambrex Bio Science,
Rockland, ME, USA) and the 150bp GP5þ/6þ amplicon was
visualised using a Clare Chemical Dark Reader transilluminator
(Clare Chemical Research, Dolores, CO, USA).
HPV genotyping was performed using the Linear Array HPV
Genotyping kit (Roche Diagnostics, Indianapolis, IN, USA). Briefly,
the assay involved amplification of samples by PCR using a master
mix which contained biotin-labelled primers for 33 HPV genotypes
(6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 55, 56, 59, 61,
62, 64, 66, 68, 69, 70, 72, 73(MM9), 81, 82(MM4), 83(MM7),
84(MM8), IS39 and CP6108) as well as the human b-globin gene.
The PCR products were chemically denatured and hybridised to
linear array strips which contained specific and one cross-reactive
oligonucleotide probes for the HPV genotypes listed above as well
as a high and low concentration of a b-globin probe. The specific
genotypes were visualised using streptavidin-horseradish peroxi-
dase conjugate and a substrate solution containing hydrogen
peroxide and 3,30,5,50-tetramethylbenzidine which yielded a blue
precipitate at the probe positions where hybridisation occurred.
Pyrosequencing
Ten samples, which were positive by nested-PCR, were not able to
be genotyped using the Linear Array kit because they were below
the detectable limit of the assay. Human papillomavirus geno-
typing of these samples was accomplished by pyrosequencing
(Biotage, Foxboro, MA, USA) performed according to the
manufacturer’s instructions. Briefly, the nested PCR was per-
formed as described above. The GP6þ primer was biotinylated at
the 30-end. The PCR product was denatured to obtain single
stranded DNA, followed by pyrosequencing using the GP5þ as the
sequencing primer. The following dispensation order was used
GCACTACGCTAGCTACTACTGACTGACTGACTGACTGACTGAC
TGACTGACTGACTGACTGACTG. To identify the HPV genotype,
sequencing results were aligned with the expected sequences for
the 37 most common HPV genotypes or blasted against HPV
sequences in the NCBI database.
Statistical analyses
Clinical and laboratory risk factors for the study population were
extracted from our head and neck database and imported to a
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performed using the Intercooled STATA (version 8.2) software
(StataCorp. LP, College Station TX, USA). Factors associated with
HPV status were selected based on cross-tabulations and
univariate logistic regression analyses. Cross-tabulations were
analysed using the w
2 test or Fisher’s exact test, where appropriate.
Logistic regression was used to perform the analyses of associa-
tions between demographic, clinical and pathologic variables with
HPV status. Crude odds ratio (OR) were first calculated. Univariate
analyses for the association of selected variables with 11q13 amp
status were performed in the subset of HPV-negative subjects to
identify possible confounding factors of association. Potential
confounders were identified based on P-values p0.1. Logistic
regression was used to calculate the relative odds of HPV status
with 11q13 amp after adjusting for the potential confounders (age,
tumour stage and site).
RESULTS
Study population demographics
Table 1 summarises the patient demographics. Approximately 64%
(80 out of 125) of the patients were males and 36% (45 out of 125)
were females. The majority of patients were current smokers
(n¼76, 61%). The majority of the study population (65%) was
dead by the last follow-up (May 2004). Our study population
ranged in age from 18 to 92 years; the median age at diagnosis was
63 years, and the median age at death was 67 years.
Human papillomavirus prevalence and genotype in
tumour specimens
Twenty-four percent (30 out of 125) of the tumours were positive
for HPV. All HPV-positive tumours contained HPV16 whereas two
out of 30 (7%) were coinfected with other HPV types. One had an
additional low-risk HPV type 11 and the other had an additional
high-risk HPV type 33 and possibly 52 (a positive hybridisation
signal for cross-reactive HPV33 probe on the HPV linear array
genotyping strip could not rule out the presence of HPV52)
(Table 1).
Distribution of tumour human papillomavirus status
according to patient characteristics
The majority of tumours occurred in the oral cavity (91 out of 125,
73%). Human papillomavirus-positive tumours occurred at
various sites throughout the oral cavity and pharynx (data not
shown). Approximately 20% (18 out of 91) of tumours from the
oral cavity were found to be HPV-positive, whereas a slightly
higher proportion of HPV-positive tumours were observed in the
oropharynx (35% (12 out of 34). When stratified by smoking
status, seven HPV-positive tumours from the oropharynx of
current smokers occurred in the base of tongue (3), soft palate (2),
tonsil (1) and an overlapping lesion of the oropharynx (1). In
contrast, the five HPV-positive tumours from the oropharynx of
nonsmokers and former smokers occurred in the tonsil (3) and
base of tongue (2) only.
Analyses of factors associated with a positive HPV status are
summarised in Table 2. Human papillomavirus-positive tumours
were less likely to occur in older individuals (o55 years. 40% were
HPV-positive vs X55 years, 19% were HPV-positive: adjusted
OR¼0.3, 95% confidence interval (CI)¼0.1–0.8), and were less
likely to carry amplified genes in chromosomal band 11q13. After
adjusting for age, tumour site and stage, 11q13 amp status was still
statistically associated with HPV status, with only 17% (five out
of 30) of HPV-positive tumours vs 44% (39 out of 89) of HPV-
negative tumours having 11q13 amp (adjusted OR¼0.2, 95%
CI¼0.1–0.6).
We evaluated the pattern of tobacco and alcohol risk behaviours
by HPV status. Although the majority of patients from both the
HPV-positive and negative groups were ever smokers and ever
drinkers (77 and 80%, respectively), these patients were no more
likely to be HPV-positive than those who never smoked or
consumed alcohol (OR¼0.8, 95% CI¼0.1–7.8). However, no
statistical interaction between alcohol and drinking habits with
HPV-positivity was observed.
Individuals with HPV-positive tumours were less likely to have
subsequent tumours, either recurrences, metastases or new
Table 1 Patient characteristics (n¼125)
Characteristic N Percent (%)
Age (years)
o35 3 2.40
36–45 9 7.20
46–55 18 14.40
56–65 43 34.40
66–75 37 29.60
76–85 13 10.40
485 2 1.60
Gender
Male 80 64.00
Female 45 36.00
Race
Caucasian 117 93.60
Other 8 6.40
Vital status
Alive 44 35.20
Dead 81 64.80
Tobacco exposure
Never 13 10.40
Former 36 28.80
Current 76 60.80
Alcohol duration/years
Never 18 14.40
Social 3 2.40
2–10 6 4.80
11–30 33 26.40
31–50 53 42.40
450 12 9.60
HPV status
Negative 95 76.00
HPV16 28 22.40
HPV16 & 11 1 0.80
HPV16, 33 & (52)
a 1 0.80
Family history cancer
No 62 49.60
Yes 63 50.40
Tumour stage
I 21 16.80
II 28 22.40
III 27 21.60
IV 49 39.20
Subsequent tumour(s)
No 61 48.80
Yes 64 51.20
Total 125 100.00
Abbreviation: HPV¼human papillomavirus.
aUnable to rule out HPV52 owing to
cross-reactivity of the HPV33 probe.
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tumours that developed in HPV-positive patients (33%, 10 out of
30) were confined to head and neck sites. In contrast, among
patients with HPV-negative tumours, 57% (54 out of 95) developed
recurrences, metastases or new primaries at head and neck sites, as
well as other sites throughout the body.
A higher proportion of HPV-positive tumours occurred in the
oropharynx. Forty percent (12 out of 30) of HPV-positive tumours
compared to 23% (22 out of 95) of HPV-negative tumours
occurred in the oropharynx (adjusted OR¼2.4, 95% CI¼1.0–5.8).
A high tumour stage (stage III & IV: adjusted OR¼1.4, 95%
CI¼0.6–3.5) and family history of cancer (adjusted OR¼1.3, 95%
Table 2 Association of patient/tumour characteristics with HPV status
Any HPV subtype
Characteristics No. positive (n¼30) No. negative (n¼95) Unadjusted OR (95% CI) Adjusted OR
a (95% CI)
Age (years)
o55 12 18 1.0 (referent)
X55 18 77 0.4 (0.1–0.9) 0.3 (0.1–0.8)
Gender
Male 23 57 1.0 (referent)
Female 7 38 0.5 (0.2–1.1) 0.5 (0.2–1.3)
Race
Caucasian 29 88 1.0 (referent)
Other 1 7 0.4 (0.1–3.7) 0.2 (0.02–2.2)
Tobacco exposure
Never 4 9 1.7 (0.5–6.1) 1.7 (0.4–6.7)
Former 10 26 1.4 (0.6–3.6) 2.4 (0.8–6.6)
Current 16 60 1.0 (referent)
Alcohol exposure
Never 4 14 1.0 (referent)
Ever 26 81 1.1 (0.3–3.7) 0.9 (0.3–3.2)
Alcohol duration
Never user 4 14 1.0 (referent)
Short-term user 3 6 1.8 (0.3–10.3) 1.3 (0.2–8.4)
Long-term user 23 75 1.1 (0.3–3.6) 0.9 (0.3–3.2)
Combined tobacco and alcohol exposure
Ever/Ever 23 76 1.0 (referent)
Never/Ever 3 5 2.0 (0.4–8.9) 1.8 (0.4–8.6)
Ever/Never 3 10 1.0 (0.3–3.9) 1.3 (0.3–5.6)
Never/Never 1 4 0.8 (0.1–7.8) 0.8 (0.1–8.3)
Family cancer history
No 13 49 1.0 (referent)
Yes 17 46 1.4 (0.6–3.2) 1.3 (0.6–3.2)
Tumour site
Oral cavity 18 73 1.0 (referent)
Oropharynx 12 22 2.2 (0.9–5.3) 2.4 (1.0–5.8)
11q13 amplification status
Not amplified 25 50 1.0 (referent)
Amplified 5 39 0.3 (0.1–0.7) 0.2 (0.1–0.6)
Not performed 0 6 —
Tumour grade
Well 8 24 1.0 (referent)
Moderate 17 52 1.0 (0.4–2.6) 1.0 (0.3–2.8)
Poor 3 11 0.8 (0.2–3.7) 0.7 (0.1–3.2)
Unknown 2 8 — —
Tumour stage
I & II 10 39 1.0 (referent)
III & IV 20 56 1.4 (0.6–3.3) 1.4 (0.6–3.5)
Recurrent, metastatic or new primary tumours
No 21 41 1.0 (referent)
Yes 9 54 0.4 (0.2–0.9) 0.4 (0.2–1.0)
Abbreviations: CI, confidence interval; HPV, human papillomavirus; OR, odds ratio.
aAdjusted for age, site and stage, where appropriate.
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positive tumours, but none of these associations were statistically
significant.
Human papillomavirus and 11q13 amplification status
according to tumour site
Amplification status at chromosomal band 11q13 was available for
119 tumours from our study population. Approximately 37% (44
out of 119) were amplified at 11q13. Figure 1 shows the frequency
of 11q13 amp stratified by tumour site and HPV status. Overall, we
detected a lower prevalence of 11q13 amp in the HPV-positive
tumours than in the HPV-negative group (17 vs 44%, respectively,
Fisher’s exact P¼0.009). In the oral cavity, 22% of the HPV-
positive tumours were amplified at 11q13, whereas 39% of the
HPV-negative tumours had 11q13 amp (Fisher’s exact P¼0.270).
In the oropharynx, a significantly smaller proportion of HPV-
positive tumours had 11q13 amp when compared with HPV-
negative tumours (8% HPV-positive vs 60% HPV-negative,
Fisher’s exact P¼0.008).
TP53 mutation status, p16 expression and 11q13
amplification status in human papillomavirus-positive
tumours
In a subset of tumours (n¼69) for which data on all three
molecular markers were available (i.e. TP53 mutation status, p16
expression and 11q13 amp status), their associations with HPV
status was assessed (Table 3). TP53 mutations were less likely to
occur in the HPV-positive HNSCC (adjusted OR¼0.4, 95%
CI¼0.0–3.1). As expected, HPV-positive tumours were more
likely to express p16 (adjusted OR¼3.0, 95% CI¼0.9–9.7). Sixty
percent (nine out of 15) of the HPV-positive tumours exhibited
high expression of p16 whereas 33% (18 out of 54) of HPV-
negative tumours expressed high levels of p16.
We classified the subpopulation according to combined p16
expression, TP53 mutation status and 11q13 amp status. Class II
included tumours that carried wild-type TP53, expressed p16 and
was not amplified at 11q13, class III included tumours that also
carried wild-type TP53 and expressed p16 but were amplified at
chromosomal band 11q13 and class I tumours were those with all
other combinations of TP53 mutation status, p16 expression and
11q13 amp status. Human papillomavirus-positive tumours were
more likely not to be amplified at 11q13 and simultaneously
overexpress p16 and contain wild-type TP53 (class II: adjusted
OR¼6.5, 95% CI¼1.8–23.9). The tumours that contained wild-
type TP53 overexpressed p16, but those with 11q13 amp were less
likely to be HPV-positive than those without 11q13 amp and were
no different from all other tumours (class III: OR¼0.9, 95%
CI¼0.1–8.9).
DISCUSSION
This retrospective study of 125 patients with first primary head
and neck tumours evaluated the association between tumour
HPV status and patient demographics, clinical risk factors and
amplification status at chromosomal band 11q13. We further
evaluated the relationship between genetic alterations: TP53
mutation status, 11q13 amp and p16 protein expression in a
subpopulation of 69 unselected tumours. Our analysis shows that
along with wild-type TP53 and p16 overexpression, HPV-positive
tumours were less likely to carry gene amplification of chromo-
somal band 11q13, which further defines the characteristic of
HPV-positive head and neck tumours and suggests a distinct
molecular pathway for HNSCC development.
The relationship between LOH at TP53, 11q13 amp and HPV has
been shown in one study including only 37 HNSCC (Rodrigo et al,
2002). Loss of heterozygosity at TP53, 11q13 amp and HPV status
were reported on only 11 (30%) of their samples and p16
overexpression was not evaluated. The study reported a lower
frequency of 11q13 amp in HPV-positive tumours (HPVþ with
11q13 amp¼2 out of 4 (50%); HPV  with 11q13 amp¼5 out of 7
(71%) but their HPV-positive tumours were more likely to have
LOH at TP53 (three out of four (75%)). Earlier studies utilising
immunohistochemistry have shown that the overexpression of p53
and p16 and reduced expression of cyclin D1 were associated with
HPV-positive tumours but 11q13 amp was not evaluated and these
studies only included tumours arising in the tonsils (Andl et al,
1998; Li et al, 2004). One other study evaluated the combined
relationship between the three molecular markers and HPV status
using immunohistochemistry (Wilczynski et al, 1998), but similar
to the earlier mentioned studies, their analysis was limited to
tumours that arose in the tonsils. In addition, the study included
tumours that were first primaries, recurrences, lymph node
metastases and lung metastases. Despite the differences in sample
size and tumour site included in these analyses, the results from
these three studies are in agreement with our findings. In our
study, the combined characteristics of TP53 mutation status,
p16 protein expression (a protein which is overexpressed as a
consequence of HPV E7 expression) and 11q13 amp (a genetic
alteration frequently observed in head and neck tumours) were
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Figure 1 Frequency of 11q13 amp according to HPV status and tumour
site.
Table 3 Association of molecular markers with HPV status
Any HPV
Molecular characteristics
No. positive
(n¼15)
No. negative
(n¼54)
Adjusted
a
OR (95% CI)
11q13 amplification status
Not amplified 13 26 1.0 (referent)
Amplified 2 28 0.1 (0.0–0.7)
TP53 mutation status
Wild-type 14 45 1.0 (referent)
Mutant 1 9 0.4 (0.0–3.1)
CDKN2A/p16 expression
Negative 6 36 1.0 (referent)
Positive 9 18 3.0 (0.9–9.7)
Three molecular
b markers combined
Class I 6 39 1.0 (referent)
Class II 8 8 6.5 (1.8–23.9)
Class III 1 7 0.9 (0.1–8.9)
Abbreviations: CI, confidence interval; HPV, human papillomavirus; OR, odds ratio.
aAdjusted for age, site and stage, where appropriate.
bThree molecular markers
combined were classified as: class II¼TP53wt, p16-positive and no 11q13
amplification. Class III¼TP53wt, p16-positive and 11q13 amplification. Class I¼all
other possible combination of TP53 mutation status, p16 expression and 11q13
amplification status.
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tumourigenesis. Tumours that were HPV-positive were more likely
to carry all three markers (wild-type TP53, express p16 and no
amplification at 11q13). We included in our analyses tumours that
were first primaries from various sites within the oral cavity and
pharynx and demonstrate that HPV-positive tumours with this
distinct molecular phenotype can arise not only in the oropharynx
(50%, four out of eight) but also in the oral cavity (50%, four out of
eight).
Our results shed further light on the multiple genetic alterations
that are commonly found in of head and neck tumours (Gollin,
2001). A genetic progression model for HNSCC has been proposed
by Califano et al (Califano et al, 1996, 2000) and describes a series
of ordered genetic changes which may occur during tumour
development. It is thought that, for the most part, early genetic
alterations include loss of chromosomal bands 9p21, 3p, 17p13 and
amplification of 11q13. The candidate genes involved in these
genetic alterations are thought to be CDKN2A/p16, the tumour
suppressor gene FHIT, TP53 and the CCND1 oncogene, respec-
tively. Examination of hyperplastic, dysplastic, carcinoma in situ
and invasive carcinoma lesions revealed increasing LOH which
corresponded with histopathological progression (Califano et al,
1996). Loss of heterozygosity at 9p21 was the most frequent
alteration in benign hyperplastic lesions, followed by LOH at 3p21
and 17p13. In addition, dysplastic lesions revealed an increased
incidence of allelic imbalance at 11q13 (benign hyperplasia: (6%),
dysplasia: (29%), carcinoma in situ: 40%, invasive carcinoma
(61%)). Our results show that HPV-positive tumours are less likely
to be amplified at 11q13 and at the same time p16 is overexpressed,
providing indirect evidence that the infection may have occurred
at an earlier time point in the carcinogenic process.
The loss of functional TP53 by mutation seems not to be
necessary in HPV-positive HNSCC, as p53 protein loss results
from increased degradation in these tumours (Wiest et al,
2002; Hafkamp et al, 2003; Braakhuis et al, 2004). The HPV E7
oncoprotein binds and degrades the RB1 tumour suppressor
protein (Boyer et al, 1996), which in turn causes the release of E2F
(a transcriptional regulator of cell proliferation genes) from pRb/
E2F complexes, permitting E2F to transactivate S-phase-related
genes. The functional inactivation of pRb by E7 leads to
overexpression of the cyclin-dependent kinase inhibitor p16
(Khleif et al, 1996). The detection of p16 expression therefore is
considered to be a surrogate marker for HPV infection, this
observation was also confirmed in our studies.
Amplification of chromosomal band 11q13 has been reported in
a number of carcinomas (head and neck, breast, lung, pancreatic,
prostate, ovarian, bladder and so on.) (Schwab, 1998). Approxi-
mately 45% of HNSCC have amplification of 11q13 (Schuuring,
1995; Lese et al, 1995). The amplification status of chromosomal
band 11q13 was determined in our study, using a sensitive
methodology, FISH with probes for FGF3/INT2, FGF4/HST1 or
CCND1 (Lese et al, 1995; Shuster et al, 2000). A significantly
smaller proportion of patients with 11q13 amp were observed in
the HPV-positive group (13%, two out of 15) compared to the
HPV-negative group (54%, 26 out of 48). One consequence of
11q13 amp is CCND1 overexpression, which is thought to play a
direct role in this disease (Callender et al, 1994). Other proto-
oncogenes which map to the 11q13 core region are amplified and
overexpressed (Huang et al, 2002), but their role in head and neck
tumour development has not yet been fully delineated. The CCND1
gene product, cyclin D1 associates with cyclin-dependent kinase 4
and 6, and this complex promotes RB1 phosphorylation and like
the HPV E7 oncoprotein, their interaction leads to the dissociation
of pRb from the transcription factor E2F. This results in transition
of the cell from G1 into S-phase. One possible explanation for
the lack of 11q13 amp in HPV-positive tumours may be that
amplification of chromosomal band 11q13 might be unnecessary,
as the resulting interaction of the HPV E7 oncoprotein with pRb
might allow the cells to be less dependent on CCND1 for cell cycle
progression. We therefore believe that the low frequency of 11q13
amp observed in our HPV-positive head and neck tumours may be
explained by a distinct mechanism for HPV carcinogenesis.
Several studies report that patients with HPV-positive head and
neck tumours have an improved prognosis (Ritchie et al, 2003;
Schlecht, 2005), whereas amplification of 11q13 has been
associated with a more rapid and frequent recurrence of disease
(Fujii et al, 2001) and poorer survival (Akervall et al, 1997; Rodrigo
et al, 2000; Namazie et al, 2002). Weinberger et al (2006) has
shown that patients with HPV-positive tumours which express
high levels of p16 protein and low levels of p53 protein present
with a favourable prognosis. We have shown in our study that
HPV-positive tumours have high levels of p16 expression and
wild-type TP53 and in addition, a low frequency of amplification at
11q13. Further analyses are warranted to determine whether this
lack of 11q13 amp also contributes to the improved prognosis
observed in patients with HPV-positive HNSCC.
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